Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 7/20 | 0.47 |
| ▸ | DRD3 | P35462 | 6/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4967479 | 0.91 | KDM4E (0.49) | MEN1KMT2ACACNA1GKDM4EALDH1A1 | |
| SCHEMBL4915589 | 0.84 | DRD2 (0.50) | CACNA1GKDM4EALDH1A1TDP1DRD2 | |
| SCHEMBL4916834 | 0.78 | DRD2 (0.58) | MEN1KMT2AKDM4EALDH1A1TDP1 | |
| SCHEMBL4917959 | 0.78 | DRD2 (0.49) | CACNA1GKDM4EALDH1A1TDP1DRD2 | |
| SCHEMBL4915621 | 0.78 | DRD2 (0.50) | CACNA1GKDM4EALDH1A1TDP1DRD2 | |
| SCHEMBL4917873 | 0.78 | KDM4E (0.48) | MEN1KMT2AKDM4EALDH1A1TDP1 | |
| SCHEMBL4907682 | 0.75 | DRD2 (0.53) | MEN1KMT2AKDM4EALDH1A1TDP1 | |
| SCHEMBL4918534 | 0.74 | HTR2A (0.53) | KDM4EALDH1A1TDP1DRD2DRD3 | |
| SCHEMBL5502071 | 0.72 | DRD3 (0.64) | MEN1KMT2AKDM4EALDH1A1TDP1 | |
| SCHEMBL5502062 | 0.72 | DRD2 (0.62) | MEN1KMT2AKDM4EALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1778685-B1 | INDOLIZINE CARBOXAMIDES AND THE AZA AND DIAZA DERIVATIVES THEREOF | SANOL ARZNEI SCHWARZ GMBH (DE) | 2008-03-26 | — | — | EP | claimed |
| US-20080051409-A1 | Indolizine Carboxamides and Aza and Diaza Derivatives Thereof | SCHWARZ PHARMA AG (DE) | 2008-02-28 | — | — | US | claimed |
| US-20080051409-A1 | Indolizine Carboxamides and Aza and Diaza Derivatives Thereof | SCHWARZ PHARMA AG (DE) | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051409-A1 | Indolizine Carboxamides and Aza and Diaza Derivatives Thereof | GRIN2A, GRIN2C, GRIN1 | MEN1 1227/4885KMT2A 455/4885CACNA1G 1044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.